search
Back to results

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Primary Purpose

Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Atorvastatin
Atorvastatin Placebo
Sponsored by
Nemours Children's Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Insulin-Dependent focused on measuring Type 1 diabetes, Children, Statins, Hypercholesterolemia, Lipoproteins, C reactive protein, Continuous glucose monitors, Adolescence, Abdominal magnetic resonance imaging, Toll like receptors, Receptors of advanced glycation end products, Nutrition

Eligibility Criteria

10 Years - 20 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:Project 1

  • T1DM diagnosed clinically for > 1 year
  • any HbA1C
  • on stable insulin therapy
  • Ages: 10 - 20 years
  • both genders
  • BMI < 85th percentile
  • Fasting LDL-C>100mg/dl
  • Normal thyroid function

Inclusion Criteria:Projects 2 and 3

  • T1DM diagnosed clinically for > 3 year
  • HbA1C > 8%
  • on stable insulin therapy
  • Ages: 12- 20 years
  • both genders
  • BMI < 85th percentile
  • Fasting LDL-C>100mg/dl
  • Normal thyroid function

Exclusion Criteria:Projects 1,2 and 3

  • Severe dyslipidemia (LDL-C >160, TG > 400 mg/dl)
  • Smoking
  • Pregnancy
  • Current use of anti-inflammatory or immunomodulatory drugs, lipid lowering, antidiabetic drugs
  • Patients with hypertension and/or microalbuminuria will be allowed using balanced randomization and standardized treatment

Sites / Locations

  • Alfred I duPont Hospital
  • Nemours Children's Clinic
  • Nemours Children's Clinic
  • Nemours Children's Clinic
  • Nemours Children's Clinic-Jefferson

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Atorvastatin

Placebo

Arm Description

Outcomes

Primary Outcome Measures

LDL-C Levels Assessed at Randomization and 6 Months
To assess if the use of statins in children with type 1 DM is safe, improves measures of LDL-C. Subjects will have a physical exam, laboratories, nutritional counseling and moderate aerobic exercise recommended. Diabetes management will be intensified. At 3 months fasting lipoprotein fractions (ion mobility)re-drawn and if LDL-C >100mg/dl patients will be randomized to treatment with statins or placebo for 6 months, randomization stratified by BP and microalbuminuria, duration of diabetes and HgA1C. At 1 month safety labs will be repeated and blood withdrawn again at 3 and 6 months from baseline.
Hs-CRP Levels Assessed at Randomization and 6 Months
To assess if the use of statins in children with type 1 DM decreases the concentration of inflammatory markers.

Secondary Outcome Measures

MAGE
Mean amplitude of glycemic excursion (MAGE) with continuous glucose monitoring (CGM - IPro®, Medtronic Minimed) worn blindly for 6d to assess glucose variability
RAGE
Receptor for Advanced Glycation End Products
Descending Aortic Strain
Subclinical atherosclerosis and arterial stiffness of abdominal aortic MRI

Full Information

First Posted
November 2, 2010
Last Updated
June 4, 2019
Sponsor
Nemours Children's Clinic
Collaborators
Pfizer, Medtronic, Quest Diagnostics-Nichols Insitute
search

1. Study Identification

Unique Protocol Identification Number
NCT01236365
Brief Title
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Official Title
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nemours Children's Clinic
Collaborators
Pfizer, Medtronic, Quest Diagnostics-Nichols Insitute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Children with type1 diabetes (T1DM) have increased risk for cardiovascular disease (CVD) due to chronic increase in the blood sugars and inflammation. If there is also increased in cholesterol, it creates a highly abnormal environment not fully corrected by improved control of the blood sugars. CVD remains the principal risk of mortality in T1DM, and its prevention and treatment, compelling in children. This grant proposal encompasses 3 separate, yet interrelated projects addressing different aspects of CVD risk in children with T1DM. Project #1: a randomized controlled trial on the safety and efficacy of a class of drugs called "statins", which lower bad cholesterol in the body, in children with diabetes and elevated bad cholesterol. We will measure changes in concentration of blood inflammatory markers and for the 1st time, correlate levels of these markers with changes in blood sugar as measured by continuous glucose sensors, instruments that measure the blood sugar continuously through a small needle under the skin. Project #2: is a laboratory study to investigate the genetics and concentration of key molecules that participate in the inflammatory cascade and atheromatous plaque formation that causes CVD. Expression levels in children with T1DM will be compared with those in healthy controls for the 1st time. Project #3: examines the use of abdominal aortic MRI to measure damage to the arteries in children with T1DM and healthy age-matched controls. The results of these studies will likely provide important new data on the use of statins in children with diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Keywords
Type 1 diabetes, Children, Statins, Hypercholesterolemia, Lipoproteins, C reactive protein, Continuous glucose monitors, Adolescence, Abdominal magnetic resonance imaging, Toll like receptors, Receptors of advanced glycation end products, Nutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Atorvastatin
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Atorvastatin
Other Intervention Name(s)
Lipitor
Intervention Description
10 or 20 mg daily
Intervention Type
Drug
Intervention Name(s)
Atorvastatin Placebo
Intervention Description
10 or 20 mg daily
Primary Outcome Measure Information:
Title
LDL-C Levels Assessed at Randomization and 6 Months
Description
To assess if the use of statins in children with type 1 DM is safe, improves measures of LDL-C. Subjects will have a physical exam, laboratories, nutritional counseling and moderate aerobic exercise recommended. Diabetes management will be intensified. At 3 months fasting lipoprotein fractions (ion mobility)re-drawn and if LDL-C >100mg/dl patients will be randomized to treatment with statins or placebo for 6 months, randomization stratified by BP and microalbuminuria, duration of diabetes and HgA1C. At 1 month safety labs will be repeated and blood withdrawn again at 3 and 6 months from baseline.
Time Frame
Randomization and 6 months
Title
Hs-CRP Levels Assessed at Randomization and 6 Months
Description
To assess if the use of statins in children with type 1 DM decreases the concentration of inflammatory markers.
Time Frame
Randomization and 6 months
Secondary Outcome Measure Information:
Title
MAGE
Description
Mean amplitude of glycemic excursion (MAGE) with continuous glucose monitoring (CGM - IPro®, Medtronic Minimed) worn blindly for 6d to assess glucose variability
Time Frame
Randomization and 6 months
Title
RAGE
Description
Receptor for Advanced Glycation End Products
Time Frame
Randomization and 6 months
Title
Descending Aortic Strain
Description
Subclinical atherosclerosis and arterial stiffness of abdominal aortic MRI
Time Frame
Randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:Project 1 T1DM diagnosed clinically for > 1 year any HbA1C on stable insulin therapy Ages: 10 - 20 years both genders BMI < 85th percentile Fasting LDL-C>100mg/dl Normal thyroid function Inclusion Criteria:Projects 2 and 3 T1DM diagnosed clinically for > 3 year HbA1C > 8% on stable insulin therapy Ages: 12- 20 years both genders BMI < 85th percentile Fasting LDL-C>100mg/dl Normal thyroid function Exclusion Criteria:Projects 1,2 and 3 Severe dyslipidemia (LDL-C >160, TG > 400 mg/dl) Smoking Pregnancy Current use of anti-inflammatory or immunomodulatory drugs, lipid lowering, antidiabetic drugs Patients with hypertension and/or microalbuminuria will be allowed using balanced randomization and standardized treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nelly Mauras, MD
Organizational Affiliation
Nemours Children's Clinic 807 Children's Way Jacksonville, Florida 32207
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alfred I duPont Hospital
City
Wilmington
State/Province
Delaware
Country
United States
Facility Name
Nemours Children's Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Nemours Children's Clinic
City
Orlando
State/Province
Florida
Country
United States
Facility Name
Nemours Children's Clinic
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32504
Country
United States
Facility Name
Nemours Children's Clinic-Jefferson
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25418907
Citation
Canas JA, Ross JL, Taboada MV, Sikes KM, Damaso LC, Hossain J, Caulfield MP, Gidding SS, Mauras N. A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes. Pediatr Diabetes. 2015 Mar;16(2):79-89. doi: 10.1111/pedi.12245. Epub 2014 Nov 22.
Results Reference
result
PubMed Identifier
25524487
Citation
McCulloch MA, Mauras N, Canas JA, Hossain J, Sikes KM, Damaso LC, Redheuil A, Ross JL, Gidding SS. Magnetic resonance imaging measures of decreased aortic strain and distensibility are proportionate to insulin resistance in adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2015 Mar;16(2):90-7. doi: 10.1111/pedi.12241. Epub 2014 Dec 18.
Results Reference
result

Learn more about this trial

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

We'll reach out to this number within 24 hrs